Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hubei Jumpcan Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600566'
s EV-to-FCF Range Over the Past 10 Years
Min: 4.36 Med: 10.69 Max: 83.89
Current: 13.39
During the past 13 years, the highest EV-to-FCF of Hubei Jumpcan Pharmaceutical Co was 83.89. The lowest was 4.36. And the median was 10.69.
SHSE:600566's EV-to-FCF is ranked better than 70.12% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.07
vs SHSE:600566: 13.39
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hubei Jumpcan Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Hubei Jumpcan Pharmaceutical Co's share price for today is ¥27.08.
Hubei Jumpcan Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hubei Jumpcan Pharmaceutical Co EV-to-FCF Related Terms
Hubei Jumpcan Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Jumpcan Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hubei Jumpcan Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hubei Jumpcan Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hubei Jumpcan Pharmaceutical Co's EV-to-FCF falls into.
Hubei Jumpcan Pharmaceutical Co's current Enterprise Value is ¥13,664 Mil.
Hubei Jumpcan Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,021 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a EV-to-FCF of 13.39 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. This is 25% above median its historical median of 10.69. Over the past decade, Hubei Jumpcan Pharmaceutical Co's EV-to-FCF has ranged from 4.36 to 83.89. According to the industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #170 out of 569 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Hubei Jumpcan Pharmaceutical Co's EV-to-FCF too high?
Hubei Jumpcan Pharmaceutical Co's current EV-to-FCF of 13.39 is 25% above median its 10-year median of 10.69. Over the past 10 years, this metric has ranged from a low of 4.36 to a high of 83.89. The Drug Manufacturers industry median EV-to-FCF is 21.07. Hubei Jumpcan Pharmaceutical Co's value of 13.39 is 36.4% below this industry median. Based on the distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #170 out of 569 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #170 out of 569 companies for EV-to-FCF. This puts Hubei Jumpcan Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 21.07. Hubei Jumpcan Pharmaceutical Co's value of 13.39 is 36.4% below this benchmark. Historically, Hubei Jumpcan Pharmaceutical Co's own EV-to-FCF has ranged from 4.36 to 83.89 over the past decade. While the company's 10-year median is 10.69 vs. the industry median of 21.07, Hubei Jumpcan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.07, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hubei Jumpcan Pharmaceutical Co's current EV-to-FCF of 13.39 is 36.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hubei Jumpcan Pharmaceutical Co's current EV-to-FCF is 13.39, which is 25% above median its own 10-year median of 10.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.02, compared to a current price of ¥27.08 — trading 28.8% above its estimated fair value. The current EV-to-FCF is 13.39, which is 25% above median its 10-year median of 10.69 and 36.4% below the Drug Manufacturers industry median of 21.07. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current EV-to-FCF is 13.39 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥27.08 is trading 28.8% above its estimated GF Value™ of ¥21.02.
GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600566:
EV-to-FCF: 13.39 (25% above median its 10-year median of 10.69)
GF Value™: ¥21.02 vs. price of ¥27.08 (28.8% above fair value)
Industry Position: 36.4% below the Drug Manufacturers median (#170 of 569)
No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hubei Jumpcan Pharmaceutical Co Business Description
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
84GF Score
Get the complete analysis for SHSE:600566
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600566 has been successfully added to your 
